Protective Vaccine & Diagnostic for Acinetobacter baumannii Infection

OVERVIEW
Bacterial infections often persist due to the formation of protective biofilms, which reduce the effectiveness of antimicrobial agents and immune effectors. *Acinetobacter baumannii* (*A. baumannii*) is an opportunistic, gram-negative bacteria that is associated with infections in health care settings and is estimated to be 2-10% of all gram-negative infections in intensive care wards. The control of *A. baumannii* has increasingly become challenging due to its ability to survive long periods of environmental exposure and the emergence of multi-drug resistant (MDR) strains. The emergence of MDR strains has created a clinical crisis with multiple reports of colistin as the therapeutic of last resort for bacterial clearance.

UMB investigators developed a candidate vaccine against *A. baumannii*, which consists of a unique set of bacterial antigens shown to be immunogenic in a rabbit infection model. Also in development is a new diagnostic test for *A. baumannii*. The diagnostic application uses the inventors' platform technology for detecting antibody response to infection in a point-of-care lateral flow assay format.

UMB researchers screened for immunoreactive proteins expressed during *in vivo* infection in a rabbit model, and identified proteins uniquely expressed in the early stages of biofilm maturation. Circulating antibodies against the early biofilm phenotype may target and eradicate the bacterial community to prevent infection.

APPLICATIONS
Effective new ways to treat and rapidly identify bacterial infections is an international healthcare priority. Gram-negative pathogens are the primary cause of hospital-acquired infections in critical care wards. The mortality rate associated with *A. baumannii* infections alone range from 26-86%, with approximately 45,000 cases in the US per year, 18,000 of which are due to multi-drug resistant strains. *A. baumannii* has been associated with chronic infections including ventilator-associated pneumonia, catheter-associated urinary tract infections, burns, endocarditis, and osteomyelitis, which are infections that establish and persist due to biofilm formation. The critical need for a vaccine against *A. baumannii* is for patients with such chronic infections, as well as military personnel at risk for trauma.

ADVANTAGES
- Unique immunogens are promising vaccine targets and infection biomarkers
- Antigens derived from early biofilm may be the key to preventing infections

STAGE OF DEVELOPMENT
Vaccine: Studies are underway to validate UMB's candidate vaccine against *A. baumannii* in animal challenge models

Diagnostic: UMB's point-of-care diagnostic platform is in advanced development, based on detection of serum antibodies by lateral flow assay. The diagnostic product will be capable of detecting multiple pathogens (e.g., *Staph aureus*) and the addition of *A. baumannii* detection to the platform is expected to be straightforward.

CONTACT INFO
Office of Technology Transfer
620 W Lexington St., 4th Floor
Baltimore, MD 21201
Email: ott@umaryland.edu
Phone: (410) 706-2380
Additional Information

INSTITUTION
University of Maryland, Baltimore

PATENT STATUS
Patent pending

LICENSE STATUS
An exclusive or nonexclusive license is available for this technology

INVESTIGATOR(S)
Mark Shirtliff
Janette Harro

ATTACHMENTS
• Download MS-2017-032 Summary.pdf

EXTERNAL RESOURCES
• Vaccines for Acinetobacter baumannii: thinking "out of the box".

DOCKET CODE
MS-2017-032

Source URL: https://www.umventures.org/technologies/protective-vaccine-diagnostic-acinetobacter-baumannii-infection